Stockscreener 앱 받기
1.57
1.29%
0.02
시간 외 거래:
1.51
-0.06
-3.82%
전일 마감가:
$1.55
열려 있는:
$1.59
하루 거래량:
353.05K
Relative Volume:
2.04
시가총액:
$118.03M
수익:
-
순이익/손실:
$-19.57M
주가수익비율:
-0.5016
EPS:
-3.13
순현금흐름:
$-17.24M
1주 성능:
-1.88%
1개월 성능:
+1.95%
6개월 성능:
-11.30%
1년 성능:
-32.91%
1일 변동 폭
$1.48
$1.6084
1주일 범위
$1.475
$1.66
52주 변동 폭
$1.33
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
명칭
Inhibikase Therapeutics Inc
전화
(302) 295-3800
주소
1000 N. WEST STREET, SUITE 1200, WILMINGTON
IKT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.57 | 116.52M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-12 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc 주식(IKT)의 최신 뉴스
Inhibikase Therapeutics Reports Q3 2025 Financials and Progress - TipRanks
Sands capital buys Inhibikase therapeutics (IKT) shares worth $3 million By Investing.com - Investing.com Australia
Sands capital buys Inhibikase therapeutics (IKT) shares worth $3 million - Investing.com India
Inhibikase Therapeutics sells 68.97M shares and pre-funded warrants at $1.45/share - MSN
Inhibikase Therapeutics Announces $93.6 Million Stock Offering - The Globe and Mail
Inhibikase Therapeutics Inc IQT0 Stock Analysis and ForecastGrowth Stock Opportunities & Interactive Learning for Better Returns - earlytimes.in
Four companies raise nearly $950M in follow-ons: Public Equity Report - biocentury.com
[8-K] Inhibikase Therapeutics, Inc. Reports Material Event | IKT SEC FilingForm 8-K - Stock Titan
[424B5] Inhibikase Therapeutics, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Net current asset value per share of Inhibikase Therapeutics, Inc. – MUN:IQT0 - TradingView
Inhibikase Shares Climb After Revised Drug Timeline, Public Offering - MarketScreener
Will Inhibikase Therapeutics Inc. (IQT0) stock beat value stocksJuly 2025 Outlook & Short-Term Trading Alerts - newser.com
Inhibikase Therapeutics Prices $100 Million Public Offering - MarketScreener
Inhibikase Therapeutics (IKT) Prices $100 Million Public Offerin - GuruFocus
Is Inhibikase Therapeutics Inc. stock a buy before product launchesJuly 2025 Drop Watch & Fast Moving Trade Plans - newser.com
Inhibikase Therapeutics, Inc. (IKT) Stock: Declines Amid $100 Million Public Offering Announcement - parameter.io
Inhibikase Therapeutics (NASDAQ: IKT) prices $100M stock, warrants offering at $1.45 - Stock Titan
Inhibikase Therapeutics announces proposed public offering and pre-funded warrants - MSN
IKT Announces Pricing Below Previous Closing Price in Latest Off - GuruFocus
Is Inhibikase Therapeutics Inc. reversing from oversold territoryTrade Signal Summary & Daily Momentum Trading Reports - newser.com
Inhibikase Therapeutics prices $100 million public offering - Investing.com
Inhibikase Therapeutics prices $100 million public offering By Investing.com - Investing.com Australia
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Inhibikase Therapeutics prices public offering of 46 million shares at $1.45 per share - MarketScreener
IKT Announces New Offering Managed by Leading Financial Firms - GuruFocus
Inhibikase Therapeutics (IKT) Launches Public Offering of Common Stock - GuruFocus
Inhibikase Therapeutics announces proposed public offering of common stock and pre-funded warrants - MarketScreener
Inhibikase Therapeutics (IKT) Launches Public Stock Offering - GuruFocus
Inhibikase Therapeutics (IKT) Plans Global Phase 3 Trial for PAH Treatment - GuruFocus
Inhibikase Therapeutics stock falls after announcing public offering By Investing.com - Investing.com South Africa
Inhibikase Therapeutics stock falls after announcing public offering - Investing.com India
Inhibikase Therapeutics Advances IKT-001 to Phase 3 Study - TipRanks
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Inhibikase Therapeutics to Initiate Pivotal Phase 3 Study for IKT-001 in Pulmonary Arterial Hypertension, Potentially Accelerating FDA Approval Timeline - Quiver Quantitative
Inhibikase (NASDAQ: IKT) starts stock, pre-funded warrant offering with 30-day 15% option - Stock Titan
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension - GlobeNewswire
Inhibikase Therapeutics (Nasdaq: IKT) Plans Single Pivotal Phase 3 PAH Trial of IKT-001 - Stock Titan
Signal strength of Inhibikase Therapeutics Inc. stock in tech scanners - newser.com
Using data models to predict Inhibikase Therapeutics Inc. stock movementRecession Risk & Scalable Portfolio Growth Ideas - newser.com
Top chart patterns to watch in Inhibikase Therapeutics Inc.Recession Risk & Low Risk Entry Point Tips - newser.com
Is Inhibikase Therapeutics Inc. (IQT0) stock overpriced at current multiples2025 Market Outlook & Smart Money Movement Tracker - newser.com
Why Inhibikase Therapeutics Inc. (IQT0) stock fits value portfolios2025 Geopolitical Influence & Advanced Swing Trade Entry Plans - newser.com
How to build a dashboard for Inhibikase Therapeutics Inc. stock2025 Top Decliners & Long-Term Safe Investment Plans - newser.com
Can volume confirm reversal in Inhibikase Therapeutics Inc.July 2025 Weekly Recap & Free Daily Entry Point Trade Alerts - newser.com
Is Inhibikase Therapeutics Inc. stock cheap compared to fundamentalsPortfolio Value Summary & AI Based Buy/Sell Signal Reports - newser.com
Will Inhibikase Therapeutics Inc. stock recover after recent dropDividend Hike & Growth Oriented Trading Recommendations - newser.com
Will Inhibikase Therapeutics Inc. (IQT0) stock draw ESG focused fundsJuly 2025 Opening Moves & Low Risk Entry Point Guides - newser.com
Understanding Inhibikase Therapeutics Inc.’s price movementInflation Watch & Fast Entry Momentum Alerts - newser.com
Key resistance and support levels for Inhibikase Therapeutics Inc. - newser.com
Inhibikase Therapeutics Inc (IKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.53%
1.88%
자본화:
|
볼륨(24시간):